Literature DB >> 23739708

Case for diagnosis.

Fernanda Guedes Lavorato1, Natália Solon Nery, Lislaine Bomm, Danielle Mann, Alexandre Carlos Gripp, Maria de Fátima Guimarães Scotelaro Alves.   

Abstract

Lichen sclerosus is a chronic inflammatory mucocutaneous disorder of unknown etiology that most commonly affects the female genitalia. Cutaneous involvement with nonhaemorrhagic bullous is very unusual. We describe a case of bullous lichen sclerosus.

Entities:  

Mesh:

Year:  2013        PMID: 23739708      PMCID: PMC3750903          DOI: 10.1590/S0365-05962013000200025

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


CASE REPORT

A 67-year-old woman, without remarkable medical or family background, presented with a 6month history of a pruritic sclerotic lesion on her abdomen. The sclerotic lesion had been accompanied by a blister on the back of the right foot for 4 months and there had been no previous trauma. Physical examination revealed several 2-4 cm, ivory colored, shiny, sclerotic lesion on the abdomen (Figure 1) and soft plaque on the back of the right foot (Figure 2). There were no other lesions on her body. An incision-al biopsy specimen revealed hyperkeratosis, atrophy of the epidermis, marked edema in the upper dermis resulting in a subepidermal blister and homogenization of collagen in the papillary dermis (Figure 3).
FIGURE 1

Ivory colored, shiny, sclerotic lesion on the abdomen

FIGURE 2

Blister on the back of the right foot

FIGURE 3

(A) Skin biopsy showing hyperkeratosis, atrophy of the epidermis, marked edema in the upper dermis resulting in a subepidermal blister and homogenization of collagen in the papillary dermis (HE 40x). (B) On detail, the marked edema in the upper dermis resulting in a subepidermal blister

Ivory colored, shiny, sclerotic lesion on the abdomen Blister on the back of the right foot (A) Skin biopsy showing hyperkeratosis, atrophy of the epidermis, marked edema in the upper dermis resulting in a subepidermal blister and homogenization of collagen in the papillary dermis (HE 40x). (B) On detail, the marked edema in the upper dermis resulting in a subepidermal blister After the diagnosis of Bullous lichen sclerosus et atrophicus was made, we started treatment with topical corticosteroid and achieved stabilization and slight improvement.

DISCUSSION

The first clinical description of lichen sclerosus (LSA) as an inflammatory dermatosis commonly affecting the female genitalia was given by Hallopeau.[1] Darier gave the first account of its histological features in 1892. Lichen sclerosus may affect all areas of the body, but it is most frequently found in the genital area of post-menopausal women. The etiology is unknown but it is believed that genetic susceptibility plays a role in the disease.[2] Lesions are white porcelain-like sclerotic commonly involving the female anogenital region. Extragenital lesions with similar morphology may be occasionally present in the absence of genital involvement. Soreness and pruritus are the most usual symptoms found. Bullous lichen sclerosus et atrophicus (BLSA) is an uncommon form of the disease and the exact etiology and prevalence is uncertain. Bullous formation is observed more frequently in the extragenital area than in the genital one. Several reports about the mechanisms of blister formation suggest that BLSA results from extensive vacuolar degeneration of the epidermal basal layer and edema in the upper dermis. It is often accompanied by disruption and loss of collagen support of the dermal capillaries, specially type VII collagen, that may result in haemorrhage within the bullae, but the pathogenesis is still controversial.[1] Some studies also have suggested that the findings of follicular keratosis and blister formation are very important in the diagnosis of extragenital LSA. The differential diagnosis includes bullous pemphigoid, epidermolysis bullosa acquisita and traumatic blisters. Numerous therapeutic modalities have been used in LSA and BLSA, including topical and systemic corticosteroid, testosterone and other hormonal treatments, topical calcineurin inhibitors, topical and systemic retinoids, ciclosporin, methotrexate and other immunosuppressive agents.[3] The bullous lesions are usually transient and heal before onset of typical plaques of the disease, which are more resistant to treatment.[4]
  4 in total

1.  Acral lichen sclerosus et atrophicus--case report.

Authors:  Fernanda de Oliveira Viana; Luíza Helena dos Santos Cavaleiro; Deborah Aben Athar Unger; Mario Fernando Ribeiro de Miranda; Arival Cardoso de Brito
Journal:  An Bras Dermatol       Date:  2011 Jul-Aug       Impact factor: 1.896

2.  British Association of Dermatologists' guidelines for the management of lichen sclerosus 2010.

Authors:  S M Neill; F M Lewis; F M Tatnall; N H Cox
Journal:  Br J Dermatol       Date:  2010-10       Impact factor: 9.302

3.  Bullous lichen sclerosus et atrophicus.

Authors:  D Hallel-Halevy; M H Grunwald; J Yerushalmi; S Halevy
Journal:  J Am Acad Dermatol       Date:  1998-09       Impact factor: 11.527

4.  Extensive bullous lichen sclerosus with scarring alopecia.

Authors:  V Madan; N H Cox
Journal:  Clin Exp Dermatol       Date:  2008-11-06       Impact factor: 3.470

  4 in total
  1 in total

1.  Bullous and hemorrhagic lichen sclerosus--Case report.

Authors:  Raquel Sucupira Andrade Lima; Gustavo Ávila Maquiné; Antônio Pedro Mendes Schettini; Mônica Santos
Journal:  An Bras Dermatol       Date:  2015 May-Jun       Impact factor: 1.896

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.